Diala El Khoury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diala El Khoury has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ara G. Hovanessian
UPR 2228 CNRS, Université Paris Descartes, 45 rue des Saints Pères, 75270 Paris Cedex 06, France
1 shared publication - Bernard Krust
CNRS-Université Paris Descartes, Unité Régulation de la Transcription de Maladies Génétique, 45 rue des Saints Pères, 75270 Paris Cedex 06, France
1 shared publication - Calaiselvy Soundaramourty
Institut national de la santé et de la recherche médicale (INSERM) U1124, Université Paris Cité, 75006 Paris, France
1 shared publication - Isabelle Nondier
Laboratoire de Physiologie Cérébrale, UMR8118, Centre National de la Recherche Scientifique, Université Paris Descartes, 45 rue des Saints Pères, 75006 Paris, France
1 shared publication
Latest Publications
- Open Access
- 3 August 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 333
Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type
Nucleolin expressed at the cell surface is a binding protein for a variety of ligands implicated in tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal RGG domain of nucleolin, the HB-19 pseudopeptide, we recently reported that targeting surface nucleolin with HB-19 suppresses progression of established human breast tumor cells in the athymic nude mice, and delays development of spontaneous melanoma in the RET transgenic mice.
- 3 August 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 333
Open AccessTargeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type
Nucleolin expressed at the cell surface is a binding protein for a variety of ligands implicated in tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal RGG domain of nucleolin, the HB-19 pseudopeptide, we recently reported that targeting surface nucleolin with HB-19 suppresses progression of established human breast tumor cells in the athymic nude mice, and delays development of spontaneous melanoma in the RET transgenic mice.